iRhythm Technologies (NASDAQ:IRTC) EVP Mervin Smith Sells 4,041 Shares

27 Feb 2026, 15:32 by Michael Walen · The Markets Daily

iRhythm Technologies (NASDAQ:IRTC – Get Free Report) EVP Mervin Smith sold 4,041 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $135.42, for a total transaction of $547,232.22. Following the completion of the sale, the executive vice president owned 20,275 shares in the company, valued at $2,745,640.50. This represents a 16.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Mervin Smith also recently made the following trade(s):

On Tuesday, February 24th, Mervin Smith sold 732 shares of iRhythm Technologies stock. The stock was sold at an average price of $140.91, for a total transaction of $103,146.12.

iRhythm Technologies Stock Up 3.1%

Shares of IRTC opened at $140.18 on Friday. The company has a debt-to-equity ratio of 4.25, a quick ratio of 4.48 and a current ratio of 4.63. iRhythm Technologies has a 52 week low of $92.52 and a 52 week high of $212.00. The stock has a market capitalization of $4.53 billion, a price-to-earnings ratio of -100.13 and a beta of 1.06. The stock has a fifty day moving average of $162.29 and a 200-day moving average of $170.73.

iRhythm Technologies (NASDAQ:IRTC – Get Free Report) last issued its quarterly earnings data on Thursday, February 19th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.27. The business had revenue of $208.89 million for the quarter, compared to analyst estimates of $202.61 million. iRhythm Technologies had a negative return on equity of 28.15% and a negative net margin of 5.96%.iRhythm Technologies’s quarterly revenue was up 27.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.04) EPS. As a group, sell-side analysts anticipate that iRhythm Technologies will post -1.98 earnings per share for the current fiscal year.

More iRhythm Technologies News

Here are the key news stories impacting iRhythm Technologies this week:

Positive Sentiment: Quarterly beat — iRhythm reported $0.29 EPS vs. $0.02 expected and revenue of $208.9M (+27% YoY), signaling accelerating sales growth that likely underpins today’s upside. MarketBeat: iRhythm earnings summary
Positive Sentiment: Institutional support — large investors (Vanguard, Tudor, RTW, Geode, UBS AM) built or increased stakes in recent quarters, supplying a backstop of long-term demand. MarketBeat: Institutional holdings
Neutral Sentiment: Analyst moves are mixed — several firms trimmed targets (Wells Fargo, JPMorgan, Canaccord) but maintained buy/overweight calls, while Citi lifted its target earlier; consensus remains a “Moderate Buy” with a ~ $212 average target. MarketBeat: Analyst coverage
Negative Sentiment: Heavy insider selling — CEO Quentin Blackford sold 25,540 shares and multiple senior executives (CFO, CAO, several EVPs and other insiders) sold additional blocks on Feb 25 at ~ $135.42, materially reducing their positions; such coordinated executive sales can be viewed negatively by markets. CEO Form 4 (SEC)
Negative Sentiment: Rising short interest — short interest climbed ~20% to ~3.4M shares (≈10.6% of float) with a ~5.1-day cover ratio, increasing downside risk if negative news follows or giving volatility if shorts cover.

Institutional Investors Weigh In On iRhythm Technologies

Institutional investors and hedge funds have recently made changes to their positions in the business. Measured Wealth Private Client Group LLC acquired a new stake in iRhythm Technologies during the third quarter worth approximately $30,000. Root Financial Partners LLC bought a new position in shares of iRhythm Technologies during the 3rd quarter worth approximately $30,000. GAMMA Investing LLC grew its position in shares of iRhythm Technologies by 48.4% during the 4th quarter. GAMMA Investing LLC now owns 184 shares of the company’s stock worth $33,000 after buying an additional 60 shares during the period. Smartleaf Asset Management LLC grew its position in shares of iRhythm Technologies by 100.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 198 shares of the company’s stock worth $34,000 after buying an additional 99 shares during the period. Finally, FNY Investment Advisers LLC bought a new stake in shares of iRhythm Technologies in the 3rd quarter valued at $34,000.

Analyst Ratings Changes

IRTC has been the topic of several recent research reports. Robert W. Baird cut their target price on shares of iRhythm Technologies from $220.00 to $200.00 and set an “outperform” rating on the stock in a research report on Friday, February 20th. JPMorgan Chase & Co. dropped their price target on shares of iRhythm Technologies from $240.00 to $215.00 and set an “overweight” rating for the company in a research note on Friday, February 20th. Evercore raised shares of iRhythm Technologies from an “in-line” rating to an “outperform” rating and boosted their price objective for the stock from $194.00 to $210.00 in a research note on Monday, January 5th. Loop Capital set a $220.00 target price on iRhythm Technologies in a research report on Friday, October 31st. Finally, Citigroup lifted their target price on iRhythm Technologies from $205.00 to $242.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $211.62.

Get Our Latest Research Report on IRTC

About iRhythm Technologies

(Get Free Report)

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.